Back to top
more

Heska Corporation (HSKA)

(Delayed Data from NSDQ)

$79.28 USD

79.28
71,295

+3.36 (4.43%)

Updated May 3, 2019 04:00 PM ET

After-Market: $79.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4

by Zacks Equity Research

AVEO Pharmaceuticals, Inc. (AVEO) reported a narrower-than-expected loss in the fourth-quarter 2016.

    Alexion (ALXN) Files for Soliris' Label Expansion in Japan

    by Zacks Equity Research

    Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).

      Parijat Sen headshot

      Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12%

      by Parijat Sen

      Gemphire Therapeutics Inc. (GEMP) moved big last session, as its shares rose over 12% on the day.

        XBiotech (XBIT) Catches Eye: Stock Moves Up 11.6% in Session

        by Zacks Equity Research

        XBiotech, Inc. (XBIT) moved big last session, as its shares rose over 11% on the day.

          Keryx's Auryxia Added to Largest Medicare Part D Plan

          by Zacks Equity Research

          Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.

            Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA

            by Zacks Equity Research

            Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Bausch + Lomb announced that the FDA has set a PDUFA date on Aug 24 for its decision on the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%.

              Mylan Receives Tentative Approval from FDA for HIV Therapy

              by Zacks Equity Research

              Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).

                Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

                by Zacks Equity Research

                Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.

                  Alnylam's LDL-Lowering Drug Positive in Phase II Study

                  by Zacks Equity Research

                  Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.

                    Alexion (ALXN) Licenses Artubus Technology for Rare Diseases

                    by Zacks Equity Research

                    Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.

                      Alkermes Starts Phase III Study to Treat Multiple Sclerosis

                      by Zacks Equity Research

                      Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.

                        Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase

                        by Zacks Equity Research

                        Shares of Valeant Pharmaceuticals (VRX) were up after investor ValueAct Capital management increased its stake in the company to 5.2%.

                          Tirthankar Chakraborty headshot

                          Top 5 Efficient Stocks to Buy Right Now

                          by Tirthankar Chakraborty

                          We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.

                            Shire's (SHPG) Cinryze Label Expanded for Pediatric Use

                            by Zacks Equity Research

                            Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.

                              Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA

                              by Zacks Equity Research

                              Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.

                                Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4

                                by Zacks Equity Research

                                Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.

                                  Allergan (AGN) and Editas Tie Up to Treat Eye Diseases

                                  by Zacks Equity Research

                                  Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.

                                    Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

                                    by Zacks Equity Research

                                    Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.

                                      Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4

                                      by Zacks Equity Research

                                      Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.

                                        Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%

                                        by Zacks Equity Research

                                        Alimera Sciences, Inc. (ALIM) shares rise almost 13% in the last trading session.

                                          Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus

                                          by Zacks Equity Research

                                          Epizyme, Inc. (EPZM) reported a loss of 60 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of 64 cents.

                                            Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4

                                            by Zacks Equity Research

                                            Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.

                                              Perrigo Launches First to Market OTC Equivalent of Rogaine

                                              by Zacks Equity Research

                                              Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).

                                                VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y

                                                by Zacks Equity Research

                                                VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period

                                                  Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed

                                                  by Zacks Equity Research

                                                  Sucampo Pharmaceuticals, Inc. (SCMP) reported adjusted earnings of 68 cents per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 49 cents by 38.8%.